Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

Exclusion Criteria

• •Additional strokes in the 12 weeks preceding the most recent stroke and in the opinion of the investigator, is not at significant risk of experiencing another stroke during the study period.
• •Spasticity in the contralateral upper limb that requires treatment.
• •Presence of fixed contractures in muscles of wrist, elbow, fingers.
• •Botulinum toxin treatment of any serotype in the 20 weeks prior to Day for upper limb spasticity and in the 12 weeks prior to Day 1 for any indication other than upper limb spasticity.
• •Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months.
• •Injection of corticosteroids or anesthetics in the study limb within 12 weeks.
• •Casting of the upper limbs within 12 weeks.
• •Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis.